Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus KAITLIB FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus KAITLIB FE.
ENSKYCE vs KAITLIB FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
KAITLIB FE (levonorgestrel/ethinyl estradiol/ferrous fumarate) is a combined hormonal contraceptive. Levonorgestrel is a progestogen that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that stabilizes the endometrium and provides cycle control. The added ferrous fumarate is an iron supplement to treat iron deficiency anemia.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet (norethindrone 1 mg and ethinyl estradiol 0.02 mg, with ferrous fumarate 35 mg) orally once daily for 28 days (21 active pills, 7 placebo/iron pills).
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal elimination half-life: 12-15 hours; clinically significant for once-daily dosing
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal: 40-60% as unchanged drug; biliary: 20-30% as metabolites; fecal: 10-20%
Category C
Category C
Oral Contraceptive
Oral Contraceptive